About this event
AI-enabled models can explore antibody design space at a scale experimental screening cannot match, but prediction does not guarantee full-length expression, target binding, or acceptable developability. This webinar connects computational prioritization with rapid physical validation.
Dr. Konrad Krawczyk (Founder and Chief Scientific Officer, NaturalAntibody) will explain how models across sequence, structure, binding, developability, and immunogenicity prioritize candidates, where they are most informative, and where sparse or biased data limits confidence. Dr. Gordon McInroy (Founder, Nuclera) will present a NaturalAntibody-designed anti-PD-1 panel covering full-length cell-free IgG expression, ELISA binding, SPR kinetics, and comparison with CHO reference data.
Together, the speakers will show how a tighter Design-Build-Test-Learn loop can remove non-binders earlier, return positive and negative data to models, and reserve mammalian capacity for better-supported candidates.
Nuclera empowers researchers to accelerate discovery with rapid, in-house access to high-quality functional proteins.